Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2019 - 2024)
Zentalis Pharmaceuticals (ZNTL) recorded quarterly Income from Non-Controlling Interests of -$28000.0 in Q1 2024, down 27.27% quarter-over-quarter from -$22000.0 in Q4 2023, and up 34.88% on a YoY basis from -$20758.6 in Q2 2023.
Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2019 - 2024) Analysis & Trends
Zentalis Pharmaceuticals' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$28000.0 for Q1 2024.
- In Q1 2024, Income from Non-Controlling Interests rose 34.88% year-over-year to -$28000.0; the TTM figure through Dec 2024 stood at -$28000.0 (up 75.44% YoY), while the FY2024 annual figure was -$28000.0, up 75.44% from the prior year.
- Income from Non-Controlling Interests was -$28000.0 for Q1 2024 at Zentalis Pharmaceuticals, down from -$22000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$12000.0 in Q3 2023 to a low of -$6.3 million in Q3 2021.
- Historically, Income from Non-Controlling Interests has averaged -$501411.8 across 5 years, with a median of -$53000.0 in 2020.
- The sharpest annual moves came in 2021 and 2022: Income from Non-Controlling Interests plunged 5628.18% in 2021, then surged 98.43% in 2022.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$53000.0 in 2020, then surged by 32.08% to -$36000.0 in 2021, then surged by 63.89% to -$13000.0 in 2022, then plunged by 69.23% to -$22000.0 in 2023, then slipped by 27.27% to -$28000.0 in 2024.
- The last three Income from Non-Controlling Interests figures came in at -$28000.0 (Q1 2024), -$22000.0 (Q4 2023), and -$12000.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Zentalis Pharmaceuticals | 260.33 Mn | 260.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Jun 30, 2023 | -37,000.00 |
| Mar 31, 2023 | -43,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Sep 30, 2022 | -99,000.00 |
| Jun 30, 2022 | -35,000.00 |
| Mar 31, 2022 | -160,000.00 |
| Dec 31, 2021 | -36,000.00 |
| Sep 30, 2021 | -6.30 Mn |
| Jun 30, 2021 | -488,000.00 |
| Mar 31, 2021 | -543,000.00 |
| Dec 31, 2020 | -53,000.00 |
| Sep 30, 2020 | -110,000.00 |
| Jun 30, 2020 | -435,000.00 |
| Mar 31, 2020 | -109,000.00 |
| Dec 31, 2019 | -40,000.00 |
| Sep 30, 2019 | -228,000.00 |
| Jun 30, 2019 | -127,000.00 |